We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Surgery in the age of biologics.
- Authors
Wong, Daniel J; Roth, Eve M; Feuerstein, Joseph D; Poylin, Vitaliy Y
- Abstract
Since the introduction of the first anti-tumor necrosis factor antibodies in the late 1990s, biologic therapy has revolutionized the medical treatment of patients with inflammatory bowel disease (IBD). Nevertheless, surgery continues to play a significant role in treating IBD patients. Rates of intestinal resection in patients with Crohn's disease or colectomy in ulcerative colitis are reducing but not substantially over the long term. An increasing variety of biologic medications are now available to treat IBD patients in various clinical situations. Consequently, a number of questions persist about how biologic medications affect the need for surgery and overall course in IBD patients. Given the trend for earlier and more frequent use of biologic medications in IBD patients, a working knowledge of the effects of these medications on surgical decision-making and outcomes is essential for the practicing colorectal surgeon and gastroenterologist. This review seeks to summarize the relevant literature surrounding biologic use and IBD surgery with a focus on the effect of biologics on the frequency, type and complications of surgery in this 'age of biologics'.
- Subjects
BIOLOGICALS; INFLAMMATORY bowel disease treatment; INFLAMMATORY bowel diseases; INTESTINAL surgery; CROHN'S disease; COLECTOMY; ULCERATIVE colitis
- Publication
Gastroenterology Report, 2019, Vol 7, Issue 2, p77
- ISSN
2052-0034
- Publication type
Article
- DOI
10.1093/gastro/goz004